Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

Grade Last Price % Change Price Change
C 31.3 -3.90% -1.27
YMAB closed down 3.9 percent on Wednesday, May 12, 2021, on 84 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical YMAB trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
50 DMA Support Bullish -3.90%
Upper Bollinger Band Walk Strength -3.90%
Wide Bands Range Expansion -3.90%
Upper Bollinger Band Touch Strength -3.90%
MACD Bullish Centerline Cross Bullish -0.22%
Upper Bollinger Band Walk Strength -0.22%
Older End-of-Day Signals for YMAB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 18 hours ago
Possible NR7 about 18 hours ago
Up 1% about 21 hours ago
Upper Bollinger Band Resistance about 21 hours ago
Down 3% about 22 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Therapeutic Product Therapeutic Products Blastoma Cancer Treatment Cancer Center Brain Tumor Metastases Glioma Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory

Is YMAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 55.215
52 Week Low 24.775
Average Volume 329,179
200-Day Moving Average 40.59
50-Day Moving Average 30.81
20-Day Moving Average 28.80
10-Day Moving Average 30.42
Average True Range 2.21
ADX 20.97
+DI 27.76
-DI 14.87
Chandelier Exit (Long, 3 ATRs ) 28.63
Chandelier Exit (Short, 3 ATRs ) 31.39
Upper Bollinger Band 33.24
Lower Bollinger Band 24.36
Percent B (%b) 0.78
BandWidth 30.84
MACD Line 0.35
MACD Signal Line -0.33
MACD Histogram 0.6804
Fundamentals Value
Market Cap 1.27 Billion
Num Shares 40.5 Million
EPS -1.83
Price-to-Earnings (P/E) Ratio -17.10
Price-to-Sales 0.00
Price-to-Book 16.71
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.00
Resistance 3 (R3) 34.25 33.61 33.55
Resistance 2 (R2) 33.61 32.92 33.48 33.40
Resistance 1 (R1) 32.45 32.49 32.13 32.20 33.25
Pivot Point 31.81 31.81 31.65 31.68 31.81
Support 1 (S1) 30.65 31.12 30.33 30.40 29.35
Support 2 (S2) 30.01 30.69 29.88 29.20
Support 3 (S3) 28.85 30.01 29.05
Support 4 (S4) 28.60